Integrated Molecular Analysis of Cancer (IMAC)

Launched by NATIONAL UNIVERSITY HOSPITAL, SINGAPORE · Mar 3, 2014

Keywords

ClinConnect Summary

The Integrated Molecular Analysis of Cancer (IMAC) trial is studying how changes in cancer cells can help doctors find better treatments for patients. Researchers are looking at tumor samples to identify specific markers and mutations that could guide therapy decisions. By understanding these molecular changes, they hope to improve the way cancer is treated, especially with new targeted therapies. The trial also aims to learn more about why some cancers become resistant to treatment and how they spread in the body.

To participate in this trial, patients must be at least 21 years old and have a confirmed diagnosis of cancer. They should be candidates for treatment and able to provide enough tumor tissue for testing. It's essential that patients can understand and agree to participate by signing an informed consent form. If you join the trial, you can expect to contribute to research that could lead to more effective cancer treatments in the future. The study is currently looking for female participants and is actively recruiting.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with histological confirmation of cancers who are candidates for systemic therapy, including molecular-targeted therapy/ biomarker-driven clinical trials.
• • 2. Patients must be ≥ 21 years old.
• • 3. All patients must have signed and dated an informed consent form.
• • 4. All patients must have sufficient tumour tissue for molecular profiling
• Exclusion Criteria:
• • Unable to provide informed consent